Secombe, K.R.Van Sebille, Y.Z.A.Mayo, B.J.Coller, J.K.Gibson, R.J.Bowen, J.M.2025-07-092025-07-092020Integrative Cancer Therapies, 2020; 19:1534735420928493-1-153473542092849-121534-73541534-7354https://hdl.handle.net/2440/145792Small molecule receptor tyrosine kinase inhibitors (SM-TKIs) are among a group of targeted cancer therapies, intended to be more specific to cancer cells compared with treatments, such as chemotherapy, hence reducing adverse events. Unfortunately, many patients report high levels of diarrhea, the pathogenesis of which remains under investigation. In this article, we compare the current state of knowledge of the pathogenesis of chemotherapy-induced diarrhea (CID) in comparison to SM-TKI–induced diarrhea, and investigate how a similar research approach in both areas may be beneficial. To this end, we review evidence that both treatment modalities may interact with the gut microbiome, and as such the microbiome should be investigated for its ability to reduce the risk of diarrhea.en© The Author(s) 2020. Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution- NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).microbiome; diarrhea; supportive care; tyrosine kinase inhibitors; chemotherapyHumansLung NeoplasmsDiarrheaAntineoplastic AgentsProtein Kinase InhibitorsMicrobiotaJournal article10.1177/15347354209284932024-02-18533627Secombe, K.R. [0000-0003-0716-238X]Coller, J.K. [0000-0002-8273-5048]Gibson, R.J. [0000-0002-4796-1621]Bowen, J.M. [0000-0003-0876-0031]